MedPath

Effectiveness of rTMS With Double-Cone-Coil in Patients With Major Depression

Not Applicable
Completed
Conditions
Depression
Interventions
Device: Left DLPFC Butterfly Coil
Device: Medial Frontal rTMS Double-Cone-Coil
Device: Placebo Stimulation
Registration Number
NCT01460758
Lead Sponsor
University of Regensburg
Brief Summary

Repetitive Transcranial Magnetic Stimulation (rTMS) is used to modulate the neuronal excitability in patients with depression. In the present study the investigators will examine whether medial frontal rTMS using a double-cone-coil proves to be superior to conventional high-frequency-rTMS applied to the left-sided prefrontal cortex with a butterfly-coil.

Detailed Description

Depression is a common mental disorder that presents with depressed mood, loss of interest, feelings of guilt or low self-worth, disturbed sleep or appetite, low energy levels and poor concentration. These problems can become chronic or recurrent and lead to substantial impairments in an individual's ability to take care of his or her everyday's responsibilities, at its worst, depression can lead to suicide. Depression can be reliably diagnosed in primary care. Antidepressant medications and brief, structured forms of psychotherapy are effective for 60-80% of those affected and can be delivered in primary care.

In patients with depression the cerebral metabolism is deranged in some specific areas such as hypoexcitability in frontal cortical areas. High-frequency rTMS of the dorsolateral prefrontal cortex (DLPFC) has been investigated for the treatment of hypoexcitability disorders. Mild antidepressant effects of rTMS applied to the left sided dorsolateral prefrontal cortex (DLPFC) using a standard butterfly coil can possibly be increased by a different stimulation protocol over the medial frontal cortex using a double-cone-coil. First hints to effectiveness of this treatment arise from case reports and therefore need replication and comparability to conventional stimulation protocols. In the present study the investigators will examine whether medial frontal rTMS using a double-cone-coil proves to be more effective to conventional high-frequency-rTMS applied to the left-sided prefrontal cortex with a butterfly-coil.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Episode of depression (unipolar or bipolar)( ICD-10)
  • Female or male between 18 and 70 years old
  • Skills to participate in all study procedures
  • 18 or more points in the Hamilton rating scale or depression
  • Stable antidepressant drugs
  • Written informed consent
Read More
Exclusion Criteria
  • Clinically relevant unstable internal or neurological comorbidity
  • Evidence of significant brain malformations or neoplasm, head injury
  • Cerebral vascular events
  • Neurodegenerative disorders affecting the brain or prior brain surgery
  • Metal objects in and around body that can not be removed
  • Pregnancy
  • Alcohol or drug abuse
  • Epilepsy or a pathological EEG
  • Heart pacemaker
  • High dose tranquillizers
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Left DLPFC Butterfly CoilLeft DLPFC Butterfly CoilHigh frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
Medial Frontal rTMS Double-Cone-CoilMedial Frontal rTMS Double-Cone-CoilHigh frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
Placebo StimulationPlacebo StimulationSham Stimulation (Conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz,2000 Stimuli each session, 110% motor threshold
Primary Outcome Measures
NameTimeMethod
Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)Day 19
Secondary Outcome Measures
NameTimeMethod
Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (Baseline versus end of treatment/ day 19)Day 19
Change in the Clinical Global Impression Scale (Baseline versus end of treatment/ day 19)Day 19
Change in the Alertness (Baseline versus follow-up I/ day 47)Day 47
Change in the Beck Depression Inventory (Baseline versus follow-up II/ day 75)Day 75
Change in the Alertness (Baseline versus end of treatment/ day 19)Day 19
Change in the Beck Depression Inventory (Baseline versus end of treatment/ day 19)Day 19
Change in the Global Assessment of Functioning scale (Baseline versus end of treatment/ day 19)Day 19
Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (Baseline versus follow-up I/ day 47)Day 47
Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (Baseline versus follow-up II/ day 75)Day 75
Change in the Beck Depression Inventory (Baseline versus follow-up I/ day 47)Day 47
Change in the Global Assessment of Functioning scale (Baseline versus follow-up I/ day 47)Day 47
Change in the Global Assessment of Functioning scale (Baseline versus follow-up II/ day 75)Day 75
Change in the Alertness (Baseline versus follow-up II/ day 75)Day 75
Change in the Clinical Global Impression Scale (Baseline versus follow-up I/ day 47)Day 47
Change in the Clinical Global Impression Scale (Baseline versus follow-up II/ day 75)Day 75

Trial Locations

Locations (1)

University of Regensburg- Dept of Psychiatry

🇩🇪

Regensburg, Germany

© Copyright 2025. All Rights Reserved by MedPath